Vivani Medical

What Vivani Medical does

Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants based on its proprietary NanoPortal platform. The company's lead candidate, NPM-139, is a subdermal semaglutide implant designed for once- or twice-yearly dosing for chronic weight management in obese or overweight patients, and is being advanced into a Phase 1 trial (SLIM-1) in Australia following positive preclinical data showing 20% weight loss sustained over more than seven months. A second semaglutide candidate, NPM-133, targets type 2 diabetes with six-month dosing, while NPM-115 (exenatide) successfully completed the LIBERATE-1 first-in-human Phase 1 study, validating the NanoPortal platform.

The company also operates Cortigent, Inc., a wholly-owned subsidiary developing brain-implant neurostimulation devices, including the Orion Visual Cortical Prosthesis System — an FDA Breakthrough Device designation investigational visual prosthesis for profoundly blind individuals — and a system for arm/hand function recovery in stroke patients. Cortigent also retains the legacy Argus II, previously marketed as the first and only FDA-approved artificial vision device.

Vivani is pre-revenue with no commercialized products; its business model is one-time licensing/partnering upon regulatory approval, supplemented by NIH grant funding (e.g., $1M for the Orion clinical study). It serves patient populations with chronic metabolic disease and profound blindness, with the GLP-1 obesity indication representing the highest-value strategic priority. The company is publicly traded on NASDAQ under ticker VANI, headquartered in Alameda, California, and has raised approximately $30.2 million in equity over the past 12 months to fund operations through the first half of 2027.

Name

Vivani Medical

Legal name

Vivani Medical, Inc.

Website

https://vivani.com

Company type

Public

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Implantable Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Pharmaceutical Preparations (2834), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

Keywords

• Implantable drug delivery
• Biopharmaceutical implants
• GLP-1 implants
• Obesity therapeutics
• Neurostimulation prosthetics

Headquarters

HQ city

Sylmar

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Drug Implant Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company. No commercialized products yet. Revenue expected upon successful development and regulatory approval of NanoPortal implant pipeline (NPM-139, NPM-133) for obesity, weight management, and type 2 diabetes.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants using its proprietary NanoPortal platform for metabolic diseases including obesity and type 2 diabetes. The lead candidate, NPM-139, is a subdermal semaglutide implant designed for once or twice-yearly dosing, with NPM-133 targeting type 2 diabetes and NPM-115 having completed the LIBERATE-1 first-in-human study. Through its wholly owned subsidiary Cortigent, the company also develops the Orion Visual Cortical Prosthesis System, an investigational neurostimulation device with FDA Breakthrough Device designation.

Product overview

Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants using its proprietary NanoPortal platform for metabolic diseases. The company's product portfolio includes NPM-139 (semaglutide implant for chronic weight management), NPM-133 (semaglutide implant for type 2 diabetes), and NPM-115 (exenatide implant used in LIBERATE-1). The company is also advancing neurostimulation technology through its subsidiary Cortigent, including the Orion Visual Cortical Prosthesis System for artificial vision and previously marketed Argus II device.

Differentiator

Problem solved

Functional benefit

Products and services

• NPM-139 A miniature, subdermal semaglutide drug implant with once or twice-yearly dosing under development for chronic weight management in obese or overweight patients. Inserted during a quick outpatient procedure to provide steady doses of medication over extended periods. Preclinical data showed 20% weight loss sustained over more than 7 months.
• NPM-133 A miniature, six-month, subdermal semaglutide drug implant under development to treat patients with type 2 diabetes. Inserted during a quick outpatient procedure and designed to provide steady doses of medication for up to six months.
• NPM-115 A miniature, six-month, subdermal exenatide implant. The first NanoPortal implant to achieve 6-month feasibility in animals, used in LIBERATE-1, the Phase 1 first-in-human application of the NanoPortal technology.
• Orion Visual Cortical Prosthesis System An investigational visual prosthesis system designed to provide artificial vision to profoundly blind individuals, featuring one of the smallest and highest-count micro-electrode neurostimulators with 60 electrodes on a cortical surface array and wireless wearable system for real-time data processing. Has FDA Breakthrough Device designation.

Quantifiable outcome

• 20% weight loss sustained over more than 7 months in preclinical NPM-139 study
• +3 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered minor and core.

• OKAVA PharmaceuticalsminorStrategic or Co-development PartnerOKAVA Pharmaceuticals announced first cat dosed in MEOW-1 study of OKV-119, the world's first GLP-1 weight loss therapy for pets, utilizing novel drug-delivery technology from Vivani Medical. The study aims to evaluate safety, tolerability, and efficacy for treating diabetes, kidney disease, and extending pet lifespans.
• UCLA (University of California, Los Angeles)coreStrategic or Co-development PartnerCortigent (subsidiary of Vivani) conducts the Orion Visual Cortical Prosthesis System Early Feasibility Study at UCLA, developing a visual prosthesis to provide artificial vision to the profoundly blind.
• Cortigent, Inc.coreOthersWholly-owned subsidiary of Vivani Medical developing precision neurostimulation systems including Orion Visual Cortical Prosthesis System for artificial vision and a new system for arm/hand function recovery in stroke patients. Vivani is exploring strategic options including potential spin-off or IPO registration for Cortigent as independent publicly traded company.

Scale indicators14 records

Recent moves3 records

Expansion highlights6 records

Broad incumbents

• Novo Nordisk: Global leader in GLP-1 therapy with Wegovy (semaglutide) for chronic weight management, the direct comparator in Vivani's SLIM-1 Phase 1 trial. Comparable as the dominant incumbent in the obesity/T2D market Vivani's NanoPortal platform targets.
• Eli Lilly: Major GLP-1 player with Mounjaro/Zepbound (tirzepatide) dominating the obesity market and advancing oral GLP-1 candidates (orforglipron). Comparable as the principal large-cap incumbent whose injectable and oral alternatives define the competitive landscape Vivani is attempting to disrupt with a long-acting implant.

Emerging players

• Viking Therapeutics: Clinical-stage biotech developing dual GLP-1/GIP receptor agonists (e.g., VK2735) for obesity. Comparable as a small-cap competitor pursuing differentiated metabolic mechanisms targeting the same obesity patient population Vivani's NPM-139 is designed to address.
• Structure Therapeutics: Clinical-stage company developing oral GLP-1 receptor agonists (GSBR-1290) for obesity and T2D. Comparable as an emerging alternative-modality competitor seeking to displace injectable GLP-1s with a more convenient dosing form.
• Altimmune: Clinical-stage biopharmaceutical company developing pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity and MASH. Comparable as a small-cap emerging player in the same metabolic-disease development space.
• Lexicon Pharmaceuticals: Clinical-stage company with metabolic and neuropathic pain programs including sotagliflozin. Comparable as a small-cap peer with overlapping metabolic-disease focus and similar financing/capital markets dynamics.
• Crinetics Pharmaceuticals: Clinical-stage company developing oral nonpeptide therapeutics for endocrine diseases including acromegaly. Comparable as a small-cap peer pursuing novel drug delivery and targeting chronic endocrine conditions.
• Neuralink: Developer of implantable brain-computer interfaces. Comparable as a neurotechnology peer relevant to the Cortigent subsidiary's Orion Visual Cortical Prosthesis and arm/hand motion recovery program.

Direct peers

• Blackrock Neurotech: Developer of neural implant technology for brain-computer interfaces, including the Utah Array used in clinical research. Comparable as a direct peer to Vivani's Cortigent subsidiary developing implanted neurostimulation systems (Orion Visual Cortical Prosthesis).
• Second Sight Medical Products: Predecessor company to Vivani's Cortigent subsidiary and original developer/marketer of the Argus II Retinal Prosthesis System. Comparable as the historical and direct peer in artificial vision implants whose technology lineage Cortigent continues.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/second-sight-medical-products
• Xx.com/Argus_BionicEye

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds20 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivani Medical